FDA Approvals – Feb 2022

In February 2022, the Food and Drug Administration (FDA) approved ciltacabtagene autoleucel for Janssen Biotech for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody.

Click here to check the previous FDA approvals for Oncology and hematology indications.